BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 28889919)

  • 1. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 blockade in renal cell cancer.
    Beckermann KE; Johnson DB; Sosman JA
    Expert Rev Clin Immunol; 2017 Jan; 13(1):77-84. PubMed ID: 27426025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
    Schmidinger M
    Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in immunotherapy for kidney cancer.
    Ball MW; Allaf ME; Drake CG
    Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors in renal cell carcinoma.
    Ross K; Jones RJ
    Clin Sci (Lond); 2017 Nov; 131(21):2627-2642. PubMed ID: 29079639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of immunotherapy in kidney cancer.
    Nazzani S; Bazinet A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
    Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
    Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy of Renal Cell Carcinoma].
    Poprach A; Lakomý R; Büchler T
    Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for genitourinary tumors.
    Nakayama T; Kitano S
    Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies.
    Ding L; Dong HY; Zhou TR; Wang YH; Yan T; Li JC; Wang ZY; Li J; Liang C
    Cancer Med; 2021 Sep; 10(18):6384-6401. PubMed ID: 34382349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers.
    Gill DM; Agarwal N
    Urol Oncol; 2017 Dec; 35(12):676-677. PubMed ID: 29054496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature.
    Rebuzzi SE; Bregni G; Grassi M; Damiani A; Buscaglia M; Buti S; Fornarini G
    Immunotherapy; 2018 Sep; 10(13):1123-1132. PubMed ID: 30236027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.
    Wynja E; Solomon B; Bleeker J
    J Immunother; 2018 Sep; 41(7):340-342. PubMed ID: 29965859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma.
    Grünwald V
    Oncol Res Treat; 2016; 39(6):353-8. PubMed ID: 27259695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.